Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population

Inclusion criteria

• Permanent healthy residents with normal intelligence meet the minimum age requirement. Literate and willing to provide written informed consent.
• A signed informed consent.
• Willing to comply with the rules of the clinical trial scheme. Accept the blood examination before and after immunization and cooperate follow-up visit.

Exclusion criteria

• Exclusion criteria of the first vaccination A person with a history of H7N9 virus infection or suspected infection; Who is allergic to any component of trial vaccine (and past history of any allergy vaccination), especially allergic to eggs; No spleen, or the spleen isn't working; Autoimmune diseases or immunodeficiency, have been treated with immunosuppressant over the past six months; Acute attack of acute illness or chronic disease in almost 7 days; Accept blood products in three months before getting inoculated testing vaccine; Got inoculated active virus vaccine in 14 days or subtype or inactivated virus in 7 days before getting inoculated testing vaccine; Who had been infected by any acute diseases ;
• Who had fever in past 3 days (axillary temperature ≥ 38 ℃);
• Who is participating another clinical trial
• Who had allergies, convulsions, epilepsy, encephalopathy, psychosis history or family history;
• Who is suffering from thrombocytopenia or other coagulation disorder, which may result to intramuscular injection contraindication; The laboratory detection indexes are abnormal before getting inoculated testing vaccine; The females are in suckling period, pregnancy, plan of pregnant or pregnancy tests (positive).
• Who had fever in the past 3 days (axillary temperature ≥ 37.1 ℃). Any other situations investigator think about may affect trial evaluation. Exclusion criteria of the second vaccination Level 3 and above allergic reactions (local and general side effect, vital signs and abnormal laboratory index) related to vaccine were appeared after the first vaccination.

Level 2 and above allergic reactions related to vaccine were appeared after the first vaccination.

-Any other situations investigator think about may affect trial evaluation.